Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 307, Issue 10, 2014, Pages R1216-R1230

  Quiniou, Christiane ^a   Domínguez Punaro, Maria ^b   Cloutier, Frank ^a   Erfani, Atefeh ^a   Ennaciri, Jamila ^a   Sivanesan, Durgajini ^d   Sanchez, Mélanie ^c   Chognard, Gaëlle ^b,c   Hou, Xin ^a   Rivera, José Carlos ^b   Beauchamp, Claudine ^e   Charron, Guy ^e   Vilquin, Marie ^b   Kuchroo, Vijay ^f   Michnick, Stephen ^d   Rioux, John D ^c,e   Lesage, Sylvie ^b,c   Chemtob, Sylvain ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MONTREAL HEART INSTITUTE   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arthritis; Cytokine receptors; Inflammation; Interleukin 23R; Peptides

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGEN; CXCL1 CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OCTAPEPTIDE; PEPTIDE 2305; PROTEIN INHIBITOR; PROTEIN P40; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR; INTERLEUKIN-23 RECEPTOR, MOUSE; OLIGOPEPTIDE; STAT3 PROTEIN, MOUSE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATORY DISEASE; JURKAT CELL LINE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; DBA MOUSE; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; SPLEEN; TIME;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; COMPUTER-AIDED DESIGN; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HEK293 CELLS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-12 RECEPTOR BETA 1 SUBUNIT; JURKAT CELLS; MALE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN; SPLEEN; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION;

EID: 84922392355     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00540.2013     Document Type: Article

References (74)

1. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914, 2003.
2. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, Powrie F. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33: 279-288, 2010.
3. Anderson ME, Tejo BA, Yakovleva T, Siahaan TJ. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem Biol Drug Des 68: 20-28, 2006.
4. Ando Y, Yang GX, Tsuda M, Kawata K, Zhang W, Nakajima T, Tsuneyama K, Leung P, Lian ZX, Okazaki K, Ridgway WM, Norman GL, Ansari AA, He XS, Coppel RL, Gershwin ME. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor β-receptor type II mice. Hepatology 56: 1418-1426, 2012.
5. Awasthi A, Riol-Blanco L, Jager A, Korn T, Pot C, Galileos G, Bettelli E, Kuchroo VK, Oukka M. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol 182: 5904-5908, 2009.
6. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370, 2003.
7. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2: 1269-1275, 2007.
8. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371-1375, 2010.
9. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-290, 2007.
10. Casadio R, Frigimelica E, Bossu P, Neumann D, Martin MU, Tagliabue A, Boraschi D. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett 499: 65-68, 2001.
11. Cayatte C, Joyce-Shaikh B, Vega F, Boniface K, Grein J, Murphy E, Blumenschein WM, Chen S, Malinao MC, Basham B, Pierce RH, Bowman EP, McKenzie BS, Elson CO, Faubion WA, Malefyt Rde W, Kastelein RA, Cua D, McClanahan TK, Beaumont M. Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease. Clin Transl Gastroenterol 3: e10, 2012.
12. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais F. Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J Biol Chem 278: 34874-34881, 2003.
13. Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells. Eur J Immunol 38: 2845-2854, 2008.
14. Chognard G, Bellemare L, Pelletier AN, Dominguez-Punaro MC, Beauchamp C, Guyon MJ, Charron G, Morin N, Sivanesan D, Kuchroo V, Xavier R, Michnick SW, Chemtob S, Rioux JD, Lesage S. The dichotomous pattern of IL-12r and IL-23R expression elucidates the role of IL-12 and IL-23 in inflammation. PLoS One 9: e89092, 2014.
15. Chow D, Ho J, Nguyen Pham TL, Rose-John S, Garcia KC. In vitro reconstitution of recognition and activation complexes between interleukin- 6 and gp130. Biochemistry 40: 7593-7603, 2001.
16. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374, 2002.
17. Christopoulos A, May LT, Avlani VA, Sexton PM. G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem Soc Trans 32: 873-877, 2004.
18. Cornelissen F, Mus AM, Asmawidjaja PS, van Hamburg JP, Tocker J, Lubberts E. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORγt in γδ T cells. Arthritis Res Ther 11: R194, 2009.
19. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748, 2003.
20. Dong C. Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 226: 80-86, 2008.
21. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463, 2006.
22. Fernandez-Fuentes N, Madrid-Aliste CJ, Rai BK, Fajardo JE, Fiser A. M4T: a comparative protein structure modeling server. Nucleic Acids Res 35: W363-W368, 2007.
23. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 29: 48-52, 2010.
24. Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Petrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hebert TE, Laporte SA. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2α-mediated Rho/ROCK signaling pathway. J Biol Chem 285: 25624- 25636, 2010.
25. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271: 16384-16392, 1996.
26. Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, Singh SP, Zhang HH, Grinberg A, Love PE, Hwang ST, Farber JM. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 119: 2317-2329, 2009.
27. 2+in cultured rat embryonic hippocampal neurons using a fluorescence microplate reader: potential application to biomolecular screening. J Pharmacol Toxicol Methods 49: 81-87, 2004.
28. Hixon JA, Anver MR, Blazar BR, Panoskaltsis-Mortari A, Wiltrout RH, Murphy WJ. Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol Blood Marrow Transplant 8: 316-325, 2002.
29. Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 7: 136-143, 2001.
30. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116: 1218-1222, 2006.
31. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4: 919-927, 2005.
32. Kenakin T. Allosteric modulators: the new generation of receptor antagonist. Mol Interv 4: 222-229, 2004.
33. Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723, 2006.
34. Kenakin T, Onaran O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23: 275-280, 2002.
35. Kenakin TP. New eyes to see texture in ligand efficacy. Nat Methods 2: 163-164, 2005.
36. Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol 168: 786-795, 2006.
37. Kimura Y, Vassylyev DG, Miyazawa A, Kidera A, Matsushima M, Mitsuoka K, Murata K, Hirai T, Fujiyoshi Y. Surface of bacteriorhodopsin revealed by high-resolution electron crystallography. Nature 389: 206-211, 1997.
38. Koshland DE, Jr. Conformational changes: how small is big enough? Nat Med 4: 1112-1114, 1998.
39. Kroenke MA, Segal BM. IL-23 modulated myelin-specific T cells induce EAE via an IFN driven, IL-17 independent pathway. Brain Behav Immun 25: 932-937, 2011.
40. Kruisbeek AM. Isolation of mouse mononuclear cells. Curr Protoc Immunol Chapter 3, Unit 3, 1, 2001.
41. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157: 105-132, 1982.
42. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96-105, 2004.
43. Lazareno S. Determination of allosteric interactions using radioligandbinding techniques. Methods Mol Biol 259: 29-46, 2004.
44. Leduc M, Hou X, Hamel D, Sanchez M, Quiniou C, Honore JC, Roy O, Madaan A, Lubell WD, Varma DR, Mancini JA, Duhamel F, Peri KG, Pichette V, Heveker N, Chemtob S. Restoration of renal functions by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure. Am J Physiol Regul Integr Comp Physiol 304: R10-R22, 2013.
45. Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther 9: 1107-1113, 2009.
46. Lysikova M, Havlas Z, Tucek S. Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res 26: 383-394, 2001.
47. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, Galzi JL. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 21: 2124-2134, 2007.
48. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51, 2007.
49. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem 279: 7254-7263 2004.
50. Murali R, Cheng X, Berezov A, Du X, Schon A, Freire E, Xu X, Chen YH, Greene MI. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci USA 102: 10970-10975, 2005.
51. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957, 2003.
52. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med 13: 26-28, 2007.
53. Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 71: 134-145, 2010.
54. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708, 2002.
55. Peri KG, Quiniou C, Hou X, Abran D, Varma DR, Lubell WD, Chemtob S. THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol 26: 389-397, 2002.
56. Presland J. Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites. Curr Opin Drug Discov Devel 8: 567-576, 2005.
57. Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, Heveker N, Lubell W, Sennlaub F, Gobeil F, Jr., Miller G, Pshezhetsky AV, Chemtob S. Development of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 180: 6977-6987, 2008.
58. Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F, Jr., Hardy P, Joyal JS, Nedev H, Duhamel F, Beauregard K, Heveker N, Saragovi HU, Guillon G, Bouvier M, Lubell WD, Chemtob S. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist. Am J Physiol Regul Integr Comp Physiol 297: R1009-R1018, 2009.
59. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68: 1793-1802, 2005.
60. Rost B, Fariselli P, Casadio R. Topology prediction for helical transmembrane proteins at 86% accuracy. Protein Sci 5: 1704-1718, 1996.
61. Rost B, Liu J. The PredictProtein server. Nucleic Acids Res 31: 3300- 3304, 2003.
62. Rykunov D, Steinberger E, Madrid-Aliste CJ, Fiser A. Improved scoring function for comparative modeling using the M4T method. J Struct Funct Genomics 10: 95-99, 2009.
63. Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-. J Interferon Cytokine Res 31: 917-926 2011.
64. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602 1997.
65. Slingsby C, Bateman OA, Simpson A. Motifs involved in protein-protein interactions. Mol Biol Rep 17: 185-195, 1993.
66. Szymczak WA, Sellers RS, Pirofski LA. IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms. Am J Pathol 180: 1547-1559, 2012.
67. Tamada T, Honjo E, Maeda Y, Okamoto T, Ishibashi M, Tokunaga M, Kuroki R. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proc Natl Acad Sci USA 103: 3135-3140, 2006.
68. Tan DC, Kini RM, Jois SD, Lim DK, Xin L, Ge R. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 494: 150-156, 2001.
69. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13 2007.
70. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 13: 722-728, 2012.
71. Xie Y, Massa SM, Ensslen-Craig SE, Major DL, Yang T, Tisi MA, Derevyanny VD, Runge WO, Mehta BP, Moore LA, Brady-Kalnay SM, Longo FM. Protein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function. J Biol Chem 281: 16,482-16,492, 2006.
72. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96, 2007.
73. Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S, Tsutsumi A, Taniguchi M, Sumida T. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med 22: 369-374, 2008.
74. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol 46: 727-734, 2005.